Alpine Immune Sciences

A unique approach to immunology

Alpine Immune Sciences was founded in 2015 by experts in the field of recombinant protein immunotherapies and a team responsible for the FDA’s approval of the world’s first cancer immunotherapy.

Alpine’s platform is based on evolving naturally-occurring immune system proteins. Using a process called ‘directed evolution’ we modify proteins native to the immune synapse, improving them to be used as therapeutic agents for oncology, autoimmune/inflammatory disorders, and other diseases.